

# ADMINISTRACIÒ de FLUIDS i VASOACTIUS en DRA

XXXI Reunió Anual de la Societat Catalana de Nefrologia

Dr. A. Roglan

SMI. Hospital de la Santa Creu i Sant Pau. UAB.



XXXI REUNIÓ ANUAL  
DE LA SOCIETAT  
CATALANA DE  
NEFROLOGIA



10, 11 i 12 DE JUNY 2015  
Hospital Moisès Broggi, Sant Joan Despí


# PREVENCIÓ DRA segons AKIN-KDIGO

## Section 2: AKI Definition

<http://www.kidney-international.org>

© 2012 KDIGO

*Kidney International Supplements* (2012) **2**, 19–36; doi:10.1038/kisup.2011.32



# FLUIDOTERAPIA

- La fluidoterapia es la “Piedra angular” del tratamiento de la sepsis/shock -**Hipovolemia sintomática**
- La resucitación precoz agresiva con fluidos puede mejorar la hipoxia tisular, la progresión a SDMO y mejorar el pronóstico
- La EGDT en el manejo de la sepsis ha demostrado mejorar el pronóstico de estos pacientes
- La EGDT también se ha demostrado eficaz en el manejo de pacientes sometidos a cirugía mayor.

# Objectiu

- **Euvolemia/estabilitat HEMODINÀMICA**
  - TAm 65-75 mmHg
  - TAm 85-95 mmHg: no millor supervivència  
Mes complicacions: ESTUDI SEPSIS-TAM

**Balanç hídric positiu inicial  
iii NECESARI I INEVITABLE !!!**

# CORRECCIÓN VOLEMIA










Fig. 1 Type of plasma volume expanders used in the ICU. Percentages based on 577 respondents



Brunkhorst et al. NEJM 2008; 358:125-39

Schortgen F et al. *Lancet* 2001; 357:911-6




*Intensive Care Med* (2010) 36:392-411  
DOI: 10.1007/s00134-009-1678-y

*Am J Respir Crit Care Med* Vol 181, pp 1128-1155, 2010  
DOI: 10.1164/rccm.200711-16645T

# A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit

The SAFE Study Investigators\*

- ✓ 6997 pacientes críticos, randomización 1:1
  - ✓ albúmina
  - ✓ s. salino




## Estudi ALBIOS, en sepsis: 1818 pac.

In sepsis, albumin provided hemodynamic advantages. In septic shock: hemodynamic-fluid balance advantages, and survived significantly more at 90 days. No differences in organ dysfunction and degree were observed.

# Effects of Fluid Resuscitation With Colloids vs Crystalloids on Mortality in Critically Ill Patients Presenting With Hypovolemic Shock The CRISTAL Randomized Trial

JAMA. 2013;310(17):1809-1817. doi:10.1001/

Figure 2. Cumulative Incidence of Death Within First 28 Days After Randomization




No. at risk	0	5	10	15	20	25
Colloids	1414	1233	1167	1124	1099	1076
Crystalloids	1443	1239	1172	1124	1089	1064


Table 4. Mortality Outcomes in Patients With Sepsis

	Colloids Group, No.		Crystalloids Group, No.		HR (95% CI)
	Patients	Deaths	Patients	Deaths	
<b>28-d Mortality</b>					
Entire population	774	215	779	226	0.95 (0.78-1.14)
HES vs isotonic saline	375	105	557	157	0.97 (0.76-1.25)
Gelatins vs isotonic saline	152	40	557	157	0.90 (0.63-1.27)
HES vs Ringer solution	375	105	37	12	0.84 (0.46-1.53)
Gelatins vs Ringer solution	152	40	37	12	0.77 (0.40-1.47)
Albumin vs isotonic saline	59	19	557	157	1.16 (0.72-1.87)
<b>90-d Mortality</b>					
Entire population	774	252	779	286	0.87 (0.73-1.03)
HES vs isotonic saline	375	120	557	197	0.89 (0.71-1.11)
Gelatins vs isotonic saline	152	47	557	197	0.84 (0.61-1.16)
HES vs Ringer solution	375	120	37	16	0.71 (0.42-1.20)
Gelatins vs Ringer solution	152	47	37	16	0.67 (0.38-1.18)
Albumin vs isotonic saline	59	22	557	197	1.07 (0.69-1.67)



**CONCLUSIONS AND RELEVANCE** Among ICU patients with hypovolemia, the use of colloids vs crystalloids did not result in a significant difference in 28-day mortality. Although 90-day mortality was lower among patients receiving colloids, this finding should be considered exploratory and requires further study before reaching conclusions about efficacy.









# Fluid Balance and Survival






# RENAL Study Investigators



Non-survivors :	643	598	508	441	328	304
Survivors :	808	805	786	753	618	632



# Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury



# Fluid overload at initiation of renal replacement therapy is associated with lack of renal recovery in patients with acute kidney injury

Michael Heung<sup>1,\*</sup>, Dawn F. Wolfgram<sup>2,\*</sup>, Mallika Kommareddi<sup>1</sup>, Youna Hu<sup>3</sup>, Peter X. Song<sup>3</sup> and

## Risk for renal recovery within 1 year of dialysis initiation

Predictor	Hazard ratio	95% CI	P-value
% FO at initiation (per 1%)	0.97	(0.95–1.00)	0.024
≥1 comorbidity	0.51	(0.30–0.89)	0.018
Baseline serum creatinine (per 1 mg/dL)	0.56	(0.37–0.87)	0.009
Use of vasopressors	0.49	(0.28–0.85)	0.011
Time between consult and initiation (per day)	0.84	(0.72–0.98)	0.025

**Conclusions.** In patients with AKI, a higher degree of fluid overload at RRT initiation predicts worse renal recovery at 1 year.

# Post-renal: Congestive Kidney Failure and Renal Tamponade



Tomado de J. Kellum

# Carrega de volum

- No es un test, es un tractament
- Infinitament més fàcil administrar volum que extraure'l
- Monitoritzar el pes: es **EL** mètode para controlar balanç.
- Al cab d'uns dies hauria de ser **menor** al del ingrés



# ESCENARIS i administració de fluids

- **1: URGÈNCIA: evident pèrdua de volum**

Signes inicials: alteració FE Na<sup>+</sup>

Signes tardans: TA, FC, oligúria, estat mental, perfusió perifèrica....

- **2: URGÈNCIA: sepsis greu o shock sèptic**

The New England Journal of Medicine

N Engl J Med, Vol. 345, No. 19 · November 8, 2001

## EARLY GOAL-DIRECTED THERAPY IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK

EMANUEL RIVERS, M.D., M.P.H., BRYANT NGUYEN, M.D., SUZANNE HAVSTAD, M.A., JULIE RESSLER, B.S.,  
ALEXANDRIA MUZZIN, B.S., BERNHARD KNOBLICH, M.D., EDWARD PETERSON, PH.D., AND MICHAEL TOMLANOVICH, M.D.,  
FOR THE EARLY GOAL-DIRECTED THERAPY COLLABORATIVE GROUP\*

Intensive Care Med (2008) 34:17-60  
DOI 10.1007/s00134-007-0934-2

SPECIAL ARTICLE

R. Phillip Dellinger  
Mitchell M. Levy  
Jean M. Carlet  
Julian Bion  
Margaret M. Parker  
Roman Jaeschke

**Surviving Sepsis Campaign:  
International guidelines for management  
of severe sepsis and septic shock: 2008**

# ESCENARIS i administració de fluids

## • 3: UCI: Responders vs Non-responders

**Table 1—Studies of Fluid Responsiveness in Septic Patients\***

Study	Fluid Challenges, No.	Responders, %	Test Used
Tavernier et al, <sup>33</sup> 1998	35	60	dDown (SPV)
Sakka et al, <sup>35</sup> 1999	57	46	ITBVI
Michard et al, <sup>32</sup> 2000	40	40	PPV
Feissel et al, <sup>34</sup> 2001	19	53	$\Delta V_{\text{peak}}$
Michard et al, <sup>36</sup> 2003	66	48	GEDVI
Feissel et al, <sup>37</sup> 2004	39	41	$\Delta IVC$
Vieillard-Baron et al, <sup>39</sup> 2004	66	30	SVC collapsibility
Barbier et al, <sup>40</sup> 2004	20	50	$\Delta IVC$
Perner and Faber, <sup>41</sup> 2006	30	47	SVV
Feissel et al, <sup>38</sup> 2007	28	64	$\Delta P_{\text{plet}}$
Osman et al, <sup>31</sup> 2007	150	43	CVP/PAOP


# METODOLOGIA

- Contorn - Forza del pols
- Mesura de flux: ETT/ETE
- "P. L. R"
- Maniobra d'oclusió telespiratoria
- Radiologia toràcica a peu de llit
- Catèter de Swan-Ganz
- Perfusió tissular: Tonometria, microdiàlisis, O<sub>2</sub> transcutani, pH tisular.

**MACROCIRCULACIÓ**

**MICROCIRCULACIÓ**  
**estudi FENICE**

# Fonaments fisiològics: Llei de Frank-Starling



# MARCADORS ESTÀTICS DE PRECARGA





FIGURE 1. Mean RAP before volume expansion in responders and nonresponders.

## Predicting Fluid Responsiveness in ICU Patients : A Critical Analysis of the Evidence

Frédéric Michard and Jean-Louis Teboul *Chest* 2002;121;2000-2008

Table 3—PAOP Before Volume Expansion in Responders and Nonresponders\*

Source	PAOP, mm Hg	
	Responders	Nonresponders
Calvin et al <sup>2</sup>	8 ± 1	7 ± 2
Schneider et al <sup>3</sup>	10 ± 1	10 ± 1
Reuse et al <sup>4</sup>	10 ± 4	10 ± 3
Diebel et al <sup>6</sup>	14 ± 7	7 ± 2†
Diebel et al <sup>7</sup>	16 ± 6	15 ± 5
Wagner and Leatherman <sup>8</sup>	10 ± 3	14 ± 4†
Tavernier et al <sup>9</sup>	10 ± 4	12 ± 3
Tousignant et al <sup>11</sup>	12 ± 3	16 ± 3†
Michard et al <sup>12</sup>	10 ± 3	11 ± 2

\*Values are expressed as mean ± SD, except for the study of Schneider et al<sup>3</sup> (mean ± SEM).

†p < 0.05 responders vs nonresponders.

# MARC. DINÀMICS: RESPOSTA VOLUM

- Aportar volum i observar efecte en **Vol. Sistòlic**/G. C. (corba Frank-Starling)
- Canvis hemodinàmics: interacció cor - pulmó en Vent. mecànica.
- "Passive Leg Raising"

# PREDIR "RESPONDERS": Ona de pols

$\Delta$  up: depends on afterload  
 $\Delta$  down: depends on preload





FIGURE 5. Relationship of arterial pressure wave and passive respiration. Compared to end-expiration, the systolic pressure and pulse pressure rise during inspiration (INSP), then fall during expiration.



De Backer D. ICM 2005; 31:517-23

Kramer A. Chest 2004; 126:1563-8

# VOLEMIA/GC per CONTOR - FORÇA DE POLS

- **1 Contorn de pressió arterial**


**PRAM:** Pressure Recording Analitical Method

**VIGILEO-FLO TRAC**

- **2 Contorn mes dilució: Força**


**Termodil. transpulmonar (PICCO)**

**LiDCO**



PPV  $\geq$  13% identifica "responders"





The Ability of Stroke Volume Variations Obtained with Vigileo/FloTrac System to Monitor Fluid Responsiveness in Mechanically Ventilated Patients

Cannesson M et al (Anesth Analg 2009;108:513-7)

## VOLUME MANAGEMENT IN CRITICALLY ILL PATIENTS: NEW INSIGHTS

M Rezende et al Clinics 2006; 61:345-50




Figure 1 - Sensitivity and specificity of arterial pulse pressure variation ( $\Delta$ PP) for discriminating between responders and nonresponders to fluid administration.

Pediatr Crit Care Med. 2008 May;9(3):341-2. Tibby S et al

Transpulmonary thermodilution: finally, a gold standard for pediatric cardiac output measurement.

# LIMITACIONES:

## Monitors de ona de pols

SVV/PPV: validats en VM ( $V_T \uparrow$ ), sense arrítmia cardíaca

Tots paràmetres: Sense validesa en BCPIAo

## Dilució transpulmonar (TDTP)

TDER: escassa interferència en TDTP

Tto. liti: contraindica dilució liti


Relaxants: interfereixen dilució liti

Injecció perifèrica: Validada en liti,  
no recomanada en altres TDTP






# PREDIR RESPONDERS


- **ECOCARDIOGRAFÍA TT:**  
canvis en diàmetre VCI  
amb respiració.




- **ECOCARDIOGRAFÍA TT/TE:**  
canvis en el flux Aòrtic.



# PREDIR RESPONDERS: P.L.R.



Monnet and Teboul ICM 2008; 34:659-63




**Fig. 3** Typical waveform of aortic blood flow during a passive leg raising (*PLR*) test and volume expansion in a patient with preload reserve. In this patient with an acute circulatory failure the increase in aortic blood flow observed during *PLR* can predict the positive response to volume expansion

**TABLE 12.3 Hemodynamic Effects of the Trendelenburg Position in Hypovolemic ICU Patients**

Parameter	Supine	Legs Up, Head Down	Change		
			%	p	Effect
Mean arterial blood pressure (mm Hg)	64	71	11	<.001	↑
Wedge pressure (mm Hg)	4.6	7.2	57	<.001	↑
Cardiac index (L/min · m <sup>2</sup> )	2.1	1.9	9	NS	↔
Systemic vascular resistance (dyne · sec/cm <sup>5</sup> · m <sup>2</sup> )	2347	2905	24	<.001	↑



Sing R. Ann Emerg Med 1994;23:564.




**Els canvis dinàmics produïts per “PLR” no s’afecten per arrítmies ni per respiració espontània**



En HTE



No en HTE  
Si ↑ PIA



No en HTE



No en HTE


# Limitacions "P.L.R"

- Risc d'aspiració: Buidat gàstric
- PIC elevada (realitzar test A)
- Sd. compartimental abd (PIA elevada) realitzar test B
- Si: mitges de compressió elàstica, shock hemorràgic i cardiogénic poden disminuir la resposta al test

Fabio Cavallaro  
Claudio Sandroni  
Cristina Marano  
Giuseppe La Torre  
Alice Mannocci  
Chiara De Waure  
Giuseppe Bello

# Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies

Intensive Care Med (2010) 36:1475–1483





## Conclusions

Passive leg raising-induced changes in cardiac output reliably predict fluid responsiveness regardless of ventilation mode, underlying cardiac rhythm and technique of measurement and can be recommended for routine assessment of fluid responsiveness in the majority of ICU population. PLR-induced changes in pulse pressure can be a viable alternative with lower predictive ability.




# Arterial pressure changes during the Valsalva maneuver to predict fluid responsiveness in spontaneously breathing patients

The present study demonstrates that arterial pressure waveform variations induced by a VM reliably predict fluid responsiveness in spontaneously breathing patients.



# Vascular Pedicle Width in Lung Edema



Normal VPW (n=83) =  $48 \pm 5$  mm  
in upright PA CXRs

FIGURE 2. Measurements of the VPW are significantly larger in patients with pulmonary edema due to congestive heart failure ( $p < 0.01$ ) or renal failure ( $p < 0.001$ ) compared to patients with pulmonary edema due to acute lung injury. PA = posteroanterior. Reproduced with permission from Milne et al.<sup>8</sup>

# MISSATGE: VOLUM en SEPSIS

For the first 6 h of severe sepsis, infuse fluids liberally, targeting  $SvO_2$  or  $ScvO_2 > 70\%$

Subsequently, do not use “maintenance” fluids

Judge the intravascular volume daily (at least)

For new hypotension, tachycardia, or unexplained oliguria, ascertain the cause and consider a fluid challenge:

When fluid challenge is of low risk, administer 500 to 1,000 mL of crystalloid;

When the risk of fluid challenge is not trivial (ALI/ARDS; oliguria; right ventricular dysfunction), use a dynamic predictor to guide fluid boluses


PLR for those with some measure of cardiac output;

PPV for those with regular rhythm and lack of spontaneous breathing;

Change in  $P_{ra}$  for those with substantial inspiratory effort

Reassess the patient frequently because the hemodynamic state changes often


# En deshidratació (UF)



La pressió arterial depèn de dos mecanismes:


- Preservació del volum sanguini
- Compensació cardiovascular

**Sí refilling pobre, pot necessitar monitorització o NA**



Deshidratación guiada por VS

$\Delta BV\%$



Deshidratación guiada por Hto "on line"


-100 ml/h

-200


-300

+100 medica. IV


# Monitorización hematocrito on-line





UF insuficiente



UF excesiva





Stop balance negativo





## Extracorporeal Ultrafiltration in Heart Failure and Cardio-Renal Syndromes

MR Costanzo, C Ronco, et al.

*Seminars in Nephrology*, Vol 32, No 1, January 2012, pp 100-




# DOPAMINA a dosi diürètica




Number at risk

	0	200	400	600	800	1000	1200	1400
Dopamine	97	16	4	2	2	1	1	0
Placebo	87	16	5	2	2	2	2	0






Mortalitat




Diàlisis



# AMINAS PRESORAS



Martin C et al *CCM* 2000; 28:2758-65



No. at Risk	0	4	8	12	16	20	24	28
Norepinephrine	821	617	553	504	467	432	412	394
Dopamine	858	611	546	494	452	426	407	386

Martin C et al. *Chest* 1993; 103:1826-31

De Backer D. et al *NEJM* 2010; 362:779-89

# Vasopressina i shock sèptic

Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine

Rusell et al NEJM 2008; 358-877-87

The Vasopressin and Septic Shock Trial did not find a difference between low-dose vasopressin and norepinephrine vs. norepinephrine alone in hemodynamic support.

However, vasopressin may be beneficial in the less severe septic shock subgroup.

Inpatients who were also treated with corticosteroids, vasopressin, compared with norepinephrine, were associated with significantly decreased mortality.

Epinephrine, phenylephrine and terlipressin can be used safely in the ICU


Holmes Curr Opin Crit Care 2009; Juny 17 Epub ahead

There is a statistically significant interaction between vasopressin and corticosteroids.

Low-dose vasopressin and corticosteroids was associated with decreased mortality and organ dysfunction compared with norepinephrine and corticosteroids.

Rusell CCM 2009: 37:1126-7

# DECISIONS TERAPÈUTIQUES



# MISSATGE amb Vasopressors

- **Conèixer els POSSIBLES fàrmacs a emprar**
- **Decidir en funció d'objectius**

GRACIAS por su atención

Preguntas ??